MENU

EXAS Stock Exact Sciences (EXAS, $70.89) entered a monthly bullish trend. Expect an Uptrend continuation

A.I.dvisor
at Tickeron.com
10/15/24
Loading...
EXAS - Exact Sciences Corp
Bullish Trend Signal
Bullish Trend
Odds of UP Trend
Tickeron

Loading...

Price: $70.89
Daily change: -$0.07 (-0.1%)
Daily volume: 1.2M
Industry: Medical Specialties
Exact Sciences Corp (EXAS, $70.89) is predicted by A.I.dvisor to grow by to $73.73 or more within the next month. Keeping in mind similar previously-analyzed scenarios where the stock trended up during the month, the odds of an Uptrend continuation are

Aroon Indicator for EXAS shows an upward move is likely

EXAS's Aroon Indicator triggered a bullish signal on September 20, 2024. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 204 similar instances where the Aroon Indicator showed a similar pattern. In of the 204 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 09, 2024. You may want to consider a long position or call options on EXAS as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXAS advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for EXAS moved out of overbought territory on September 20, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Moving Average Convergence Divergence Histogram (MACD) for EXAS turned negative on September 26, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EXAS broke above its upper Bollinger Band on October 11, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.065) is normal, around the industry mean (22.779). P/E Ratio (0.000) is within average values for comparable stocks, (83.568). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.074) is also within normal values, averaging (42.680).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EXAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

View a ticker or compare two or three
EXAS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of proprietary technologies for the detection of cancer

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
5505 Endeavor Lane
Phone
+1 608 284-5700
Employees
6600
Web
https://www.exactsciences.com